New Research Identifies Fat-Producing Enzyme as Key Driver of Parkinson’s Disease Damage
Scientists at NTU Singapore have uncovered a potential new target for treating Parkinson’s disease. Researchers from the Lee Kong Chian School of Medicine found that a specific fat-producing enzyme in brain cells may play a critical role in driving the cellular damage associated with the disease.
- The enzyme glycerol-3-phosphate acyltransferase (GPAT) amplifies the harmful effects of the protein α-synuclein.
- GPAT alters how brain cells process fats, leading to a “double hit” of mitochondrial impairment and increased toxicity.
- Reducing GPAT activity showed a decrease in brain cell damage in laboratory experiments using fruit flies and mouse brain cells.
Understanding the Role of GPAT in Neurodegeneration
Parkinson’s disease is characterized by the accumulation of a protein called α-synuclein in the brain. Even as this protein is a known factor in the disease, the new research highlights how the enzyme GPAT exacerbates the situation. By altering the way brain cells process fats, GPAT increases the toxicity of α-synuclein, making the environment more damaging to neurons.
The “Double Hit” to Brain Cells
The study reveals that GPAT contributes to cellular damage through two simultaneous mechanisms, creating what researchers describe as a “double hit”:
1. Mitochondrial Impairment
Mitochondria serve as the “power stations” of the cell, generating the energy required to keep them functioning. The research found that GPAT contributes to damage that impairs these mitochondria, significantly reducing the cells’ ability to produce energy.
2. Increased Protein Toxicity
At the same time that energy production is compromised, GPAT increases the toxicity of α-synuclein. This combined effect accelerates the degradation of brain cells.
Potential for New Treatments
Since Parkinson’s disease currently has no cure, identifying specific enzymes that drive damage is a vital step toward developing new therapies. In laboratory settings, scientists reduced the activity of GPAT and observed a corresponding decrease in brain cell damage within mouse brain cells and fruit flies.
Frequently Asked Questions
What is GPAT?
GPAT, or glycerol-3-phosphate acyltransferase, is a fat-producing enzyme found in brain cells.
How does this discovery help Parkinson’s patients?
While this is laboratory-based research, it identifies GPAT as a potential new target for medical treatments aimed at reducing the toxicity of α-synuclein and protecting mitochondrial function.
What is α-synuclein?
It is a protein that accumulates in the brains of individuals with Parkinson’s disease and is associated with cellular damage.
Looking Forward
The findings from NTU Singapore provide critical insights into how fat metabolism influences the progression of neurodegenerative diseases. By understanding the relationship between GPAT and α-synuclein, researchers can continue to explore strategies to protect brain cells and potentially slow the progression of Parkinson’s disease.